Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mesenchymal stem cells are multipotent progenitor cells found in bone marrow, adipose tissue, and other tissues, distinguished by their ability to self-renew and differentiate into osteogenic, adipogenic, chondrogenic, and, under some conditions, myogenic lineages. This differentiation contributes to tissue regeneration and repair, making MSCs a key focus in regenerative medicine. Differentiation is regulated by signaling pathways such as Wnt/β-catenin and TGF-β, along with transcription factors like RUNX2 for osteogenesis, SOX9 for chondrogenesis, and PPARγ for adipogenesis. MSCs can be identified by specific cell surface and lineage markers. While clinically promising, applications require careful consideration of differentiation potential, biomarker status, and safety concerns, as MSC therapies operate via complex biological processes rather than the action of individual molecular targets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mesenchymal stem cell (MSC) (MSC).